Список литературы

1. Martinez E, Taminiau B., Rodriguez C., Daube G. Gut Microbiota Composition Associated with Clostridioides difficile Colonization and Infection. Pathogens. 2022; 11(7):781. doi: 10.3390/pathogens11070781

2. Tagliaferri AR, Murray K, Michael P. A Case of Pseudomembranous Colitis of Unknown Etiology. Cureus. 2022; 14(2): e21914. doi: 10.7759/cureus.21914

3. Chandrasekaran R., Lacy DB. The role of toxins in Clostridium difficile infection. FEMS Microbiol Rev. 2017; 41(6):723 - 750. doi: 10.1093/femsre/fux048

4. Abdul Jabbar S, Sundaramurthi S, Elamurugan TP, Goneppanavar M, Nelamangala RVP. An Unusual Presentation of Pseudomembranous Colitis. Cureus. 2019; 11(4):e4570. doi: 10.7759/cureus.4570

5. Czepiel J, Drozdz M, Pituch H, Kuijper EJ, Perucki W, Mielimonka A et al. Clostridium difficile infection: review. Eur J Clin Microbiol Infect Dis. 2019; 38(7):1211 - 1221. doi: 10.1007/s10096-019-03539-6

6. De Roo A.C, Regenbogen SE. Clostridium difficile Infection: An Epidemiology Update. Clin Colon Rectal Surg. 2020; 33(2):49 - 57. doi: 10.1055/s-0040-1701229

7. Lawson PA, Citron DM, Tyrrell KL, Finegold SM. Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O'Toole 1935) Preevot 1938. Anaerobe. 2016; 40:95-9. doi: 10.1016/j.anaerobe.2016.06.008

8. Khurana S, Kahl A, Yu K, DuPont AW. Recent advances in the treatment of Clostridioides difficile infection: the ever-changing guidelines. Fac Rev. 2020; 9: 13. doi: 10.12703/b/9-13

9. Couturier J, Franconeri L, Janoir C, Ferraris L, Syed-Zaidi R, Youssouf A et al. Characterization of Non-Toxigenic Clostridioides difficile Strains Isolated from Preterm Neonates and In Vivo Study of Their Protective Effect. J Clin Med. 2020; 9(11):3650. doi: 10.3390/jcm9113650

10. McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018; 66(7): e1-e48. doi: 10.1093/cid/cix1085

11. Baktash A, Terveer EM, Zwittink RD, Hornung BVH, Corver J, Kuijper EJ, Smits WK. Mechanistic insights in the success of fecal microbiota transplants for the treatment of Clostridium difficile infections. Front Microbiol. 2018; 9:1242. doi: 10.3389/fmicb.2018.01242

12. Kochan TJ, Somers MJ, Kaiser AM, Shoshiev MS, Hagan AK, Hastie JL et al. Intestinal calcium and bile salts facilitate germination of Clostridium difficile spores. PLoS Pathog. 2017; 13(7): e1006443. doi: 10.1371/journal.ppat.1006443

13. Sehgal K, Khanna S. Gut microbiome and Clostridioides difficile infection: a closer look at the microscopic interface. Therap Adv Gastroenterol. 2021; 14. doi: 10.1177/1756284821994736

14. Thornton CS, Rubin JE, Greninger AL, Peirano G, Chiu CY, Pillai DR. Epidemiological and genomic characterization of community-acquired Clostridium difficile infections. BMC Infect Dis 2018; 18: 443. doi: 10.1186/s12879-018-3337-9

15. Fu Y, Luo Y, Grinspan AM. Epidemiology of community-acquired and recurrent Clostridioides difficile infection. Therap Adv Gastroenterol. 2021; 14. doi: 10.1177/17562848211016248

16. Gazzola A, Panelli S, Corbella M, Merla C, Comandatore F, De Silvestri A et al. Microbiota in Clostridioides difficile-Associated Diarrhea: Comparison in Recurrent and Non-Recurrent Infections. Biomedicines. 2020 Sep; 8(9): 335. doi: 10.3390/biomedicines8090335

17. Singh T, Bedi P, Bumrah K, Singh J, Rai M, Seelam S. Updates in treatment of recurrent Clostridium difficile infection. J Clin Med Res. 2019; 11(7):465 - 471. doi: 10.14740/jocmr3854

18. Успенский Ю.П., Барышникова Н.В. Антибиотик- ассоциированная диарея в условиях стационара: частота встречаемости и вопросы профилактики. Медицинский алфавит. 2021; (20):35 - 37. doi: 10.33667/2078-5631-2021-20-35-37

19. Guh AY, Mu Y, Winston LG, Lohnston H, Olson D, Farley MM et al. Trends in U.S. burden of Clostridioides difficile infection and outcomes. N Engl J Med 2020; 382: 1320 - 1330. doi: 1056/NEJMoa1910215

20. Centers for Disease Control and Prevention. 2018 Annual report for the emerging infections program for Clostridioides difficile infection. Atlanta, GA: CDC, 2020.

21. Baker SJ, Chu DI. Physical, Laboratory, Radiographic, and Endoscopic Workup for Clostridium difficile Colitis. Clin Colon Rectal Surg. 2020; 33(2): 82 - 86. doi: 10.1055/s-0039-3400474.

22. Czepiel J, Biesiada G, Dr d M, Gdula-Argasinska J, Zuranska J, Marchewka J et al. The presence of IL-8 +781 T/C polymorphism is associated with the parameters of severe Clostridium difficile infection. Microb Pathog. 2018; 114:281 - 285. doi: 10.1016/j.micpath.2017.11.066

23. Kwon JH, Reske KA, Hink T, Burnham CAD, Dubberke ER. Evaluation of Correlation between Pretest Probability for Clostridium difficile Infection and Clostridium difficile Enzyme Immunoassay Results. J Clin Microbiol. 2017; 55(2):596 - 605. doi: 10.1128/JCM.02126-16

24. Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, Wilcox MH. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clinical Infectious Diseases. 2021; 73(5):e1029-e1044. doi: 10.1093/cid/ciab549

25. Kukla M, Adrych K, Dobrowolska A, Mach,T, Regu a J, Rydzewska G. Guidelines for Clostridium difficile infection in adults. Gastroenterology Rev 2020; 15 (1): 1 - 21. doi: 10.5114/pg.2020.93629

26. Guh AY, Kutty PK. Clostridioides difficile Infection. Ann Intern Med. 2018; 169(7):ITC49-ITC64. doi: 10.7326/AITC201810020

27. Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, Stollman NH. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Am J Gastroenterol. 2021;116(6):1124 - 1147. doi: 10.14309/ajg.0000000000001278. 2022; 28(12):1204 - 1219. doi: 10.3748/wjg.v28.i12.1204

28. Mamieva Z, Poluektova E, Svistushkin V, Sobolev V, Shifrin O, Guarner F, Ivashkin V. Antibiotics, gut microbiota, and irritable bowel syndrome: What are the relations? World J Gastroenterol. 2022; 28(12):1204 - 1219. doi: 10.3748/wjg.v28.i12.1204

29. Kampouri E, Croxatto A, Prod'hom G, Guery B. Clostridioides difficile Infection, Still a Long Way to Go. J Clin Med. 2021; 10(3):389. doi: 10.3390/jcm10030389

30. Шелыгин Ю.А., Алешкин В.А., Сухина М.А., Миронов А.Ю., Брико Н.И., Козлов Р.С. и соавт. Клинические рекомендации национальнои ассоциации специалистов по контролю инфекции, связанных с оказанием медицинскои помощи и общероссии скои общественнои некоммерческои организации "ассоциации колопроктологов россии" по диагностике, лечению и профилактике clostridium difficile-ассоциированнои диареи (CDI). Колопроктология, 2018; 65(3):7 - 23. doi: 10.33878/2073-7556-2018-0-3-7-23

31. C.Carroll Karen, Mizusawa Masako. Laboratory Tests for the Diagnosis of Clostridium difficile. Clin Colon Rectal Surg. 2020; 33(2):73 - 81. doi: 10.1055/s-0039-3400476

32. Драпкина О.М., Лазебник Л.Б., Бакулин И.Г., Журавлева М.С., и др. Инфекция Clostridioides difficile: диагностика, лечение и профилактика Клинические рекомендации Российского научного медицинского общества терапевтов, Научного общества гастроэнтерологов России, Общества гастроэнтерологов и гепатологов "Северо-Запад". Экспериментальная и клиническая гастроэнтерология. 2023; (2):4 - 32. https://doi.org/10.31146/1682-8658-ecg-210-2-4-32

33. Sucher A, Biehle L., Smith A., Tran C. Updated Clinical Practice Guidelines for C difficile Infection in Adults. Allana Sucher et al., US Pharmacist, 46 (12), 2021: HS10-HS16

34. Mattana M, Tomasello R, Cammarata C, Di Carlo P, Fasciana T, Giordano G, Lucchesi A, Siragusa S, Napolitano M. Clostridium difficile Induced Inflammasome Activation and Coagulation Derangements. Microorganisms. 2022 Aug 10; 10(8):1624. doi: 10.3390/microorganisms10081624. PMID: 36014040; PMCID: PMC9416296.

35. Iffland, A.; Zechel, M.; Lewejohann, J.-C.; Edel, B.; Hagel, S.; Hartmann, M.; L ffler, B.; R del, J. Experience with PCR Testing for Enteric Bacteria and Viruses of Emergency Department Patients with Acute Gastroenteritis: Are There Implications for the Early Treatment of Clostridioides difficile Infection? Antibiotics 2024, 13, 243. https://doi.org/10.3390/ antibiotics13030243

36. Nelson RL, Suda KJ, Evans CT. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults. Cochrane Database of Systematic Reviews. 2017; 3(3):CD004610. doi: 10.1002/14651858.CD004610.pub5

37. Bass SN, Lam SW, Bauer SR, Neuner EA. Comparison of oral vancomycin capsule and solution for treatment of initial episode of severe Clostridium difficile Infection. J Pharm Pract. 2015; 28(2):183 - 188. doi: 10.1177/0897190013515925

38 uon C, Wannier R, Sterken D, Fang MC., Wolf J, Prasad PA. Are Antimotility Agents Safe for Use in Clostridioides difficile Infections? Results From an Observational Study in Malignant Hematology Patients. Mayo Clin Proc Inn Qual Out. 2020; 4(6):792 - 800. doi:: 10.1016/j.mayocpiqo.2020.06.005

39. Johnson S, Louie TJ, Gerding DN, Cornely OA, Chasan - Taber S, Fitts D, Gelone SP, Broom C, Davidson DM. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis. 2014; 59:345 - 354. doi: 10.1093/cid/ciu313

40. Waqas M, Mohib K, Saleem A, LNU M, Arjumand S, Khalil HH, Nosheen R, Abbas S, Maqsood KM, Abbas K. Rifaximin Therapy for Patients With Metronidazole-Unresponsive Clostridium difficile Infection. Cureus. 2022; 14(4):e24140. doi: 10.7759/cureus.24140.

41. Sirbu BD, Soriano MM, Manzo C, Lum J, Gerding DN, Johnson S. Vancomycin Taper and Pulse Regimen With Careful Follow-up for Patients With Recurrent Clostridium difficile Infection. Clin Infect Dis. 2017; 65(8):1396 - 1399. doi: 10.1093/cid/cix529

42. Major G, Bradshaw L, Boota N, Sprange K, Diggle M, Montgomery A, Jawhari A, Spiller RC. Follow-on RifAximin for the Prevention of recurrence following standard treatment of Infection with Clostridium Difficile (RAPID): a randomised placebo controlled trial. Gut. 2019; 68(7):1224 - 1231. doi: 10.1136/gutjnl-2018-316794

43. Garey KW, Ghantoji SS, Shah DN, Habib M, Arora V, Jiang ZD, Du Pont HL. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother. 2011; 66(12):2850-5. doi: 10.1093/jac/dkr377.

44. Ng Qin X, Loke W, Foo NX, Yin M, Yeo WS, Soh AYS. A systematic review of the use of rifaximin for Clostridium difficile infections. Anaerobe. 2019; 55:35 - 39. doi: 10.1016/j.anaerobe.2018.10.011

45. Neal MD, Alverdy JC, Hall DE, Simmons RL, Zuckerbraun BS. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg. 2011; 254(3):423-7; discussion 427-9. doi: 10.1097/SLA.0b013e31822ade48

46. Juo YY, Sanaiha Y, Jabaji Z, Benharash P. Trends in Diverting Loop Ileostomy vs Total Abdominal Colectomy as Surgical Management for Clostridium difficile Colitis. JAMA Surg. 2019; 154(10):899 - 906. doi: 10.1001/jamasurg.2019.2141

47. Wang JW, Kuo CH, Kuo FC, Wang YK, Hsu WH, Yu FJ et al. Fecal microbiota transplantation: Review and update. J Formos Med Assoc. 2019; 118 Suppl 1:S23 - S31. doi: 10.1016/j.jfma.2018.08.011

48. Brandt LJ, Aroniadis OC, Mellow M, Kanatzar A, Kelly C, Park T et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012; 107(7):1079 - 1087. doi: 10.1038/ajg.2012.60

49. Madoff SE, Urquiaga M, Alonso CD, Kelly CP. Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials. Anaerobe. 2020; 61:102098. doi: 10.1016/j.anaerobe.2019.102098

50. Hvas CL, Dahl J rgensen SM, J rgensen SP, Storgaard M, Lemming L, Hansen MM, Erikstrup C, Dahlerup JF. Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection.Gastroenterology. 2019; 156(5):1324 - 1332.e3. doi: 10.1053/j.gastro.2018.12.019

51. Peng Z, Ling L, Stratton CW, Li C, Polage CR, Wu B, Tang YW. Advances in the diagnosis and treatment of Clostridium difficile infections. Emerg Microbes Infect. 2018; 7(1):15. doi: 10.1038/s41426-017-0019-4

52. Baur D, Gladstone BP, Burkert F, Carrara E, Foschi F, Dobebe S, Tacconelli E. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis. 2017; 17(9):990 - 1001. doi: 10.1016/S1473-3099(17) 30325-0

53. Moore SC. Clostridium difficile: more challenging than ever. Crit Care Nurs Clin North Am. 2018; 30(1):41 - 53. doi: 10.1016/j.cnc.2017.10.004

54. Ивашкин В.Т., Абдулганиева Д.И., Алексеенко С.А., Горелов А.В., Захарова И.Н. и соавт. Практические рекомендации Научного сообщества по содеи ствию клиническому изучению микробиома человека (НСОИМ) и России скои гастроэнтерологическои ассоциации (РГА) по применению пробиотиков, пребиотиков, синбиотиков и обогащенных ими функциональных пищевых продуктов для лечения и профилактики заболевании гастроэнтерологического профиля у детеи и взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021; 31(2):65 - 91. doi: 10.22416/1382-4376-2021-31-2-65-91

55. Lau C.S., Chamberlain R.S. Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Int J Gen Med. 2016; 9:27 - 37. doi: 10.2147/IJGM.S98280

56. Shen NT, Maw A, Tmanova LL, Pino A, Ancy K, Crawford CV, Simon MS, Evans AT. Timely Use of Probiotics in Hospitalized Adults Prevents Clostridium difficile Infection: A Systematic Review With Meta-Regression Analysis. Gastroenterology. 2017; 152(8):1889 - 1900. doi: 10.1053/j.gastro.2017.02.003

57. Vald s-Varela L, Gueimonde M, Ruas-Madiedo P. Probiotics for Prevention and Treatment of Clostridium difficile Infection. Adv Exp Med Biol. 2018; 1050:161 - 176. doi: 10.1007/978-3-319-72799-8_10

58. Gaisawat MB, MacPherson CW, Tremblay J, Piano A, Iskandar MM, Tompkins TA, Kubow S. Probiotic Supplementation in a Clostridium difficile-Infected Gastrointestinal Model Is Associated with Restoring Metabolic Function of Microbiota. Microorganisms. 2020; 8(1):60. doi: 10.3390/microorganisms8010060

59. Lacotte PA, Simons A, Bouttier S, Malet-Villemagne J, Nicolas V, Janoir C. Inhibition of In Vitro Clostridioides difficile Biofilm Formation by the Probiotic Yeast Saccharomyces boulardii CNCM I-745 through Modification of the Extracellular Matrix Composition. Microorganisms. 2022; 10(6):1082. doi: 10.3390/microorganisms10061082

60. Kelly CP, Chong-Nguyen C, Palmieri LJ, Pallav K, Dowd SE, Humbert L. et al. Saccharomyces boulardii CNCM I-745 modulates the fecal bile acids metabolism during antimicrobial therapy in healthy volunteers. Front. Microbiol. 2019; 10:336. doi: 10.3389/fmicb.2019.00336.

61. Ka mierczak-Siedlecka K, Ruszkowski J, Fic M, Folwarski M, Makarewicz W. Saccharomyces boulardii CNCM I-745: A Non-bacterial Microorganism Used as Probiotic Agent in Supporting Treatment of Selected Diseases. Current Microbiology. 2020; 77(9):1987 - 1996. doi: 10.1007/s00284-020-02053-9.

62. Goldenberg JZ, Yap C, Lytvyn L, Lo CK, Beardsley J, Mertz D, Johnston BC. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst. Rev. 2017; 12(12):CD006095. doi: 10.1002/14651858.CD006095.pub4

63. Wombwell E, Patterson ME, Bransteitter B, Gillen LR. The Effect of Saccharomyces boulardii Primary Prevention on Risk of Hospital-onset Clostridioides difficile Infection in Hospitalized Patients Administered Antibiotics Frequently Associated With C. difficile Infection. Clin Infect Dis. 2021; 73(9):2512 - 2518. doi: 10.1093/cid/ciaa808

64. Maraolo AE, Mazzitelli M, Zappulo E, Scotto R, Granata G, Andini R et al. Oral Vancomycin Prophylaxis for Primary and Secondary Prevention of Clostridioides difficile Infection in Patients Treated with Systemic Antibiotic Therapy: A Systematic Review, Meta-Analysis and Trial Sequential Analysis. Antibiotics (Basel). 2022; 11(2):183. doi: 10.3390/antibiotics11020183

65. Tariq R, Laguio-Vila M, Waqas Tahir M, Orenstein R, Pardi DS, Khanna S. Efficacy of oral vancomycin prophylaxis for prevention of Clostridioides difficile infection: a systematic review and meta-analysis. Therap Adv Gastroenterol. 2021; 14:1756284821994046. doi: 10.1177/1756284821994046

66. Kaki R, Brooks A, Main C, Jayaratne P, Mertz D. Does extending Clostridium difficile treatment in patients who are receiving concomitant antibiotics reduce the rate of relapse? Internet J Infect Dis. 2016; 15(1):1 - 5. doi: 10.5580/IJID.37585

67. Van Hise NW, Bryant AM, Hennessey EK, Crannage AJ, Khoury JA, Manian FA. Efficacy of oral vancomycin in preventing recurrent Clostridium difficile infection in patients treated with systemic antimicrobial agents. Clin Infect Dis. 2016; 63(5):651-3. doi: 10.1093/cid/ciw401

68. Carignan A, Poulin S, Martin P, Labbe AC, Valiquette L, Ali-Bachari H, Montpetit LP, Pepin J. Efficacy of secondary prophylaxis with vancomycin for preventing recurrent Clostridium difficile infections. Am J Gastroenterol. 2016; 111(12):1834 - 1840. doi: 10.1038/ajg.2016.417

69. McFarland LV, Evans CT, Goldstein EJC. Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis. Front Med (Lausanne). 2018; 7(5):124. doi: 10.3389/fmed.2018.00124

70. Raseen T, Devvrat Y, Muhammad Waqas T, Kanika S, Darrell P, Sahil K. S136 Efficacy of Saccharomyces boulardii for Prevention of Clostridioides difficile Infection: A Systematic Review and Meta-Analysis. The American Journal of Gastroenterology. 2021; 116:59 - 60. doi: 10.14309/01.ajg.0000773016.43460.eb

71. Alonso CD, Mahoney MV: Bezlotoxumab for the prevention of Clostridium difficile infection: a review of current evidence and safety profile. Infect Drug Resist. 2018; 12:1 - 9. doi: 10.2147/IDR.S159957.

72. Gerding DN, Kelly CP, Rahav G, Lee C, Dubberke ER, Kumar PN et al. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence. Clin Infect Dis. 2018; 67(5):649 - 656. doi: 10.1093/cid/ciy171

73. Basu A, Prabhu VS, Dorr MB, Golan Y, Dubberke ER, Cornely OA et al. Bezlotoxumab Is Associated With a Reduction in Cumulative Inpatient-Days: Analysis of the Hospitalization Data From the MODIFY I and II Clinical Trials. Open Forum Infect Dis. 2018; 5(11):218. doi: 10.1093/ofid/ofy218

74. Hengel RL, Ritter TE, Nathan RV, Van Anglen LJ, Schroeder CP, Dillon RJ et al. Real-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study. Open Forum Infect Dis. 2020; 7(4):097. doi: 10.1093/ofid/ofaa097